Orchid Pharma Limited Releases Q1 FY2026-27 Financial Results; Announces Completion of Strategic Acquisitions and Amalgamation
Orchid Pharma Limited has released its unaudited Limited Reviewed Financial Results for the first quarter of the financial year 2026-27, which ended on June 30, 2026. The results include both standalone and consolidated figures and have been approved by the Board of Directors at a meeting held on August 14, 2026.The statutory auditors of the company issued an unmodified conclusion on the unaudited Standalone and Consolidated results.
Q1 FY2026-27 Financial Performance Snapshot
The standalone financial results show Net Sales/Income from operations at 30,417.13 lakhs of Indian Rupees for the quarter ended June 30, 2026. The company reported a Total Income of 31,421.85 lakhs in the quarter.Key figures from the standalone results are detailed below (all amounts in lakhs of Indian Rupees):
| Particulars | Q1 FY2026-27 (Unaudited) | Previous Period |
|---|---|---|
| Net Sales / Income from operations | 30,417.13 | 36,832.71 (March 31, 2026 Revised) |
| Other Income | 1,004.72 | 1,372.81 (March 31, 2026 Revised) |
| Total Income (1+2) | 31,421.85 | 38,205.52 (March 31, 2026 Revised) |
| Total Expenses | 30,228.13 | 34,917.21 (March 31, 2026 Revised) |
| Profit / (Loss) before tax (5+6) | 1,193.72 | 3,288.31 (March 31, 2026 Revised) |
Consolidated results for the quarter ended June 30, 2026, reported Net Sales / Income from operations at 30,417.13 and Total Income at 30,599.97 lakhs. The company recorded a Profit/(Loss) before tax of 264.95 lakhs in the consolidated results for this period.
Strategic Business Developments
In addition to the financial reporting, Orchid Pharma Limited confirmed several major strategic developments:- Amalgamation: The Transferor Company, Dhanuka Laboratories Limited, was successfully amalgamated into Orchid Pharma Limited pursuant to a Scheme sanctioned by the National Company Law Tribunal (NCLT), which became effective on July 10, 2026.
- Global Antibiotic Control: The company completed the acquisition of 100% assets of AIIecra Therapeutics GmbH and Allecra Therapeutics SAS. This transaction ensures Orchid Pharma Limited possesses full global ownership of Enmetazobactam (the international brand name known as EXBLIFE), effectively completing the repatriation of this novel antibiotic molecule to India.
- European Subsidiary: The company acquired 100% share capital of Weilchensee 1272. V V GmbH, incorporating it as a wholly owned subsidiary, Orchid Pharma Europe GmbH effective from July 30, 2025.
QIP Net Funds Utilization Update
The Statement provided details on the utilization of net proceeds totaling 39,454 lakhs that were raised in a Qualified Institutional Placement (QIP) on June 27, 2023. The allocation among various objects has been revised subsequent to shareholder resolutions dated September 20, 2025.The utilization of the funds as of June 30, 2026, is summarized in the table below:
| Particulars | Amount as stated in the Offer Document (Rs. in Lakhs) | Total amount utilized up to June 30, 2026 ( Rs. In Lakhs) | Balance amount as on June 30, 2026 kept In Fixed deposits (Rs. In Lakhs) |
|---|---|---|---|
| Investment in OBPL (Subsidiary) for setting up Jammu Manufacturing Facility | 13,500 | 9,762 | 3,738 |
| Repayment/prepayment of outstanding borrowings | 19,546 | 19,546 | - |
| Funding capital expenditure (API Facility in Alathur) | 36 | 36 | - |
| General corporate purposes | 6,372 | 6,372 | - |
The total amount utilized is 35,716 lakhs, leaving a balance of 3,738 lakhs held in fixed deposits.
ORCHPHARMA Stock Price Movement
On Friday, shares of Orchid Pharma Limited edged higher to close at ₹1045.65 after rising 0.98% in trading. The stock settled well within its daily range, closing amid a low of ₹1035 and with 64,474 shares traded.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: